• Vericel Corporation recently reported record third-quarter results, posting US$67.5 million in revenue and net income of US$5.07 million, significantly improving from a net loss in the prior year, while reaffirming full-year 2025 revenue guidance of US$272 million to US$276 million.
• Progress in MACI franchise growth, including a 25% revenue increase, expanded sales initiatives, and the launch of MACI Arthro instruments contributed to strong operational momentum and ongoing pipeline development.
• We'll assess how Vericel's record MACI-driven growth and reaffirmed guidance impact its market expansion outlook and long-term investment story.

We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Vericel Investment Narrative Recap

To be a shareholder in Vericel, you need to believe in the company's ability to drive consistent growth from its flagship MACI franchise, expand into new indications, and manage operational costs as it builds out its manufacturing and sales infrastructure. The recent record third-quarter results and raised profitability have reinforced optimism around Vericel's current growth trajectory, but have not fundamentally changed the most important short-term catalyst: broadening MACI's market adoption with new procedure types, while the biggest risk remains the company's reliance on a narrow product portfolio.

One of the most relevant recent announcements is the FDA approval and subsequent launch of MACI Arthro instruments, which directly contributed to MACI's 25% revenue growth this quarter. This move supports ongoing pipeline expansion and sales momentum, aligning closely with the main catalyst of increasing surgeon adoption and market penetration for MACI.

However, even with expanding indications and strong recent numbers, investors should be aware of the continued risk that comes from...

Vericel's narrative projects $469.3 million in revenue and $75.9 million in earnings by 2028. This requires 23.5% yearly revenue growth and a $68.8 million increase in earnings from $7.1 million today.

Uncover how Vericel's forecasts yield a $53.88 fair value, a 38% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members offer fair value estimates for Vericel ranging from US$5.52 to US$53.88, highlighting two distinct perspectives. As you consider this diversity, keep in mind that the company's rapid MACI-driven growth remains a major factor influencing future performance and expectations.

Explore 2 other fair value estimates on Vericel - why the stock might be worth as much as 38% more than the current price!

Build Your Own Vericel Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Vericel research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Vericel research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vericel's overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.